$NBP 4 SEC Filings

Filed On	Filing
19 Oct 2026	Form 4: Woo Ian Ying, Director Received 13,271 shares by exercise or conversion
21 Sep 2026	Form 4: Dennis Phillip Andrew, Chief Medical Officer Received 23,695 shares by exercise or conversion · Sold 8,209 shares ($5.83K)
11 Sep 2026	Form 4: Cao Sean Wuxiong, Chief Bus. Development Officer Sold 107,978 shares ($79.9K)
08 Sep 2026	Form 4: Cao Sean Wuxiong, Chief Bus. Development Officer Received 339,372 shares by exercise or conversion
01 Sep 2026	Form 4: Xu Cong Claire, EVP, Clinical Development Received 9,382 shares by exercise or conversion · Sold 3,282 shares ($2.59K)
25 Aug 2026	Form 4: Lenz Robert A., Director Received 17,218 shares by exercise or conversion
10 Jul 2026	Form 4: Hagler Mark Arnold, Chief Commercial Officer Granted 949,050 2025 Employee Share Option (right to buy)
10 Jul 2026	Form 4: Lin Liwei Lorraine, General Counsel Granted 254,780 2025 Employee Share Option (right to buy)
08 Jul 2026	Form 4: Gupta Srishti, Director Granted 3,000,000 2025 Employee Share Option (right to buy)
07 Jul 2026	Form 4: Xu Cong Claire, SVP, Clinical Development Received 12,432 shares by exercise or conversion · Sold 4,485 shares ($3.99K)
30 Jun 2026	Form 4: Fu Wei, Director Granted 2,900,580 2025 Employee Share Option (right to buy) · Granted 1,010,100 Restricted Share Units
24 Jun 2026	Form 4: Cao Sean Wuxiong, Director Granted 181,280 Restricted Share Units · Granted 181,290 2025 Employee Share Option (right to buy)
22 Jun 2026	Form 4: Dennis Phillip Andrew, Chief Medical Officer Received 23,695 shares by exercise or conversion · Sold 8,494 shares ($5.61K)
02 Jun 2026	Form 4: Xu Cong Claire, SVP, Clinical Development Received 9,382 shares by exercise or conversion · Sold 3,494 shares ($13.8K)
18 May 2026	Form 4: Cao Sean Wuxiong, Director Sold 21,399 shares ($42.6K)
28 Apr 2026	Form 4: Hagler Mark Arnold, See Remarks Bought 230,000 shares ($577K)

Comments